Here are 1-3 brief analogies for Intensity Therapeutics (INTS):

• A very early-stage Bristol Myers Squibb or Merck, aiming to discover the next breakthrough in cancer immunotherapy.
• Like a Moderna or BioNTech in its clinical trial phase, but focused on a novel platform for directly injecting cancer therapies into tumors.
• A clinical-stage Amgen or Genentech, aspiring to develop groundbreaking new treatments for cancer.

• INT2306: An investigational, intratumoral immuno-oncology drug candidate designed to destroy solid tumors and stimulate an anti-tumor immune response.

Intensity Therapeutics (INTS) is a clinical-stage oncology company focused on developing proprietary, novel, intratumoral, immune-based product candidates for the treatment of solid tumor cancers. As a clinical-stage biotechnology company, Intensity Therapeutics is primarily engaged in research and development and conducting clinical trials for its product candidates, such as INT2306.

Therefore, at its current stage, Intensity Therapeutics does not have any commercially approved products on the market, nor does it generate revenue from product sales to major customers. Consequently, the company does not have "major customers" in the traditional sense, either companies or individuals, that purchase its products or services.

If and when Intensity Therapeutics' product candidates receive regulatory approval and are commercialized, their future "customers" would primarily be:

• Healthcare providers (e.g., hospitals, oncology clinics, cancer centers, and individual oncologists) who would administer the approved drug to patients.
• Potentially, large pharmaceutical or biotechnology companies, if Intensity Therapeutics chooses to license or partner the commercialization rights for its approved drugs.

However, as of now, Intensity Therapeutics is pre-commercial and does not have major customers.

Lewis H. Bender, Chairman of the Board, President and CEO

Mr. Bender is the founder of Intensity Therapeutics and has served as President and Chief Executive Officer since April 2012. He has over 28 years of biopharmaceutical leadership experience and has guided products from discovery to approval using novel drug delivery techniques. Before founding Intensity Therapeutics, Mr. Bender was the CEO of Interleukin Genetics, a publicly traded personalized medicine company, from January 2008 to August 2012. At Interleukin, he restructured the company, significantly increased sales, developed a new genetic testing platform, and partnered with an insurance provider for product reimbursement. Prior to Interleukin Genetics, he held various positions at Emisphere Technologies, Inc., a publicly traded drug delivery company, from 1993 to December 2007, including Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. During his career, Mr. Bender has successfully raised capital from institutional investors through multiple types of transactions and has partnered with major pharmaceutical and biotech companies.

Joseph Talamo, Chief Financial Officer

Mr. Talamo has served as Chief Financial Officer of Intensity Therapeutics since December 2023 and possesses over 25 years of experience in financial leadership roles within biopharmaceutical companies. Before joining Intensity Therapeutics, he was the Senior Vice President and Chief Financial Officer of HiberCell, Inc., a clinical-stage biotechnology company, from 2020 to 2023. Prior to that, Mr. Talamo held several senior positions at Caladrius Biosciences, Inc., a publicly traded clinical-stage biopharmaceutical company, from 2011 to 2020, serving as Senior Vice President and Chief Financial Officer from 2015 to 2020. From 1996 to 2010, he also held various senior roles at OSI Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, including Vice President and Corporate Controller from 2006 to 2010.

John Wesolowski, Principal Accounting Officer and Controller

Mr. Wesolowski has been the Principal Accounting Officer and Controller at Intensity Therapeutics since March 2017. He also served as Interim Chief Financial Officer from June 2023. Before joining Intensity Therapeutics, Mr. Wesolowski was the Director of Costing in the Yale University Controller's office from 1998 to 2016, where he managed financial reporting, property tax, and overhead and benefit rate calculations.

Kimberly A. Guedes, Vice President of Clinical Operations

Ms. Guedes is a seasoned professional with 30 years of experience in clinical development and operations, covering pre-clinical, Phase I-IV trials, translational research, and various drug development disciplines. Her experience includes roles at Yale University School of Medicine, Keiferx, Centrexion Therapeutics, Merck Pharmaceuticals, Bristol Myers-Squibb, and Mitsubishi Pharmaceuticals.

Doranne Frano, Regulatory Affairs and Quality Control

Ms. Frano is a global life science regulatory, clinical, and quality professional with over 40 years of experience in pharmaceuticals, biotechnology, medical devices, diagnostics, and regulatory compliance. She began her career in Clinical Research at G.D. Searle and has since moved into executive regulatory and quality roles.

Intensity Therapeutics (INTS) is a clinical-stage biotechnology company developing intratumoral immunotherapy products for solid tumors. Their lead product candidate, INT230-6, targets several cancer indications, with addressable market sizes identified for soft tissue sarcoma and triple-negative breast cancer.

For **soft tissue sarcoma**, the addressable market in the U.S. includes approximately 157,000 patients, with 12,000 new cases diagnosed annually and 6,000 deaths per year. Intensity Therapeutics' Phase 3 INVINCIBLE-3 study for metastatic sarcoma is actively enrolling patients across the U.S., Canada, Europe (France, Germany, Italy, Poland, and Spain), and Australia.

For **triple-negative breast cancer (TNBC)**, the U.S. market was valued at $584.3 million in 2022. Annually, approximately 287,850 new cases of invasive breast cancer are diagnosed in women in the U.S. The company is also conducting a Phase 2/3 program for TNBC, with its INVINCIBLE-4 study for presurgical TNBC expecting to enroll patients in Switzerland and France.

The broader **global intratumoral cancer therapies market**, which encompasses the types of treatments Intensity Therapeutics is developing, was valued at approximately USD 210.07 billion in 2023 and is projected to reach nearly USD 410.62 billion by 2030. Another estimate places the global market at USD 153.8 billion in 2024, growing to USD 435.6 billion by 2035. For the top seven major markets (US, EU4, UK, and Japan), the intratumoral cancer therapies market was valued at USD 457.8 billion in 2024, with a projected increase to USD 669.1 billion by 2035.

Intensity Therapeutics (INTS), a clinical-stage biotechnology company, anticipates several key drivers for its future revenue growth over the next 2-3 years, primarily stemming from the progression and potential commercialization of its lead investigational product, INT230-6. These drivers are largely dependent on successful clinical trial outcomes and securing adequate funding.

1. Advancement and Commercialization of INT230-6 in Soft Tissue Sarcoma (INVINCIBLE-3 Study): The successful progression and eventual commercialization of INT230-6 through its Phase 3 INVINCIBLE-3 study for second and third-line treatment of certain soft tissue sarcoma subtypes represent a significant potential revenue driver. This study aims to enroll 333 patients across eight countries, with overall survival as the primary endpoint. While new patient enrollment and site activations were paused in March 2025 due to funding constraints, the company intends to restart enrollment, highlighting the importance of this program for future revenue.
2. Advancement and Commercialization of INT230-6 in Triple-Negative Breast Cancer (INVINCIBLE-4 Study): The ongoing Phase 2 INVINCIBLE-4 study evaluating INT230-6 in early-stage, operable triple-negative breast cancer (TNBC) is another crucial driver. This study, which is recruiting patients in Switzerland and France and is expected to reinitiate patient enrollment in Q1 2026 after a dosing regimen amendment, could pave the way for a larger Phase 3 trial and potential market entry in a challenging cancer indication.
3. Positive Clinical Data and Increased Awareness: The publication of promising clinical trial data, such as the IT-01 study results demonstrating a 75% disease control rate and extended median overall survival in advanced cancer patients, along with presentations at major medical conferences, can significantly enhance the company's visibility and attract further investment or strategic partnerships. This increased awareness of INT230-6's efficacy and unique mechanism of action could accelerate its path to market.
4. Strategic Partnerships and Sufficient Funding: While not a direct revenue source, securing additional funding and establishing strategic partnerships are critical enablers for Intensity Therapeutics to complete its clinical trials and move towards commercialization. The company has actively been raising capital to extend its cash runway, recognizing that sustained operations and trial advancement depend on robust financial backing.
5. Expansion of INT230-6 Applications and DfuseRx Platform Leverage: Beyond the current lead indications, INT230-6 has shown activity across over 20 different cancer types in earlier studies. Successful outcomes in the ongoing trials could allow Intensity Therapeutics to explore additional indications, broadening the market potential for INT230-6. Furthermore, the proprietary DfuseRx technology platform, which enables enhanced intratumoral delivery of cancer agents, represents a valuable asset that could lead to further drug candidates or collaborative opportunities.

Share Issuance

• Since the beginning of the third quarter of 2025, Intensity Therapeutics has raised $13.6 million in gross proceeds through various offerings, including At-the-Market (ATM) sales and a registered direct offering.
• In July 2025, the company generated $6.6 million in gross proceeds (net proceeds of $6.3 million) by selling 19,868,658 shares of common stock through its At-the-Market (ATM) offering at an average price of $0.3323 per share.
• In April 2025, Intensity Therapeutics completed a public offering which resulted in approximately $2.35 million in gross proceeds from the sale of 3,133,333 shares of common stock and accompanying warrants.

Inbound Investments

• On December 5, 2024, Intensity Therapeutics announced a seed funding round, raising $3.65 million.

Capital Expenditures

• Research and development expenses, which are the primary focus of capital allocation for product development, increased to $10.5 million for the year ended December 31, 2024, from $4.8 million in 2023.
• These expenditures were primarily directed towards advancing the INVINCIBLE-3 Study (Phase 3 trial for soft tissue sarcoma) and the INVINCIBLE-4 Study (Phase 2 study for presurgical triple-negative breast cancer).
• In the second quarter of 2025, research and development expenses decreased to $1.5 million, mainly due to the pausing of new patient enrollment in the INVINCIBLE-3 pivotal trial due to funding limitations.